zipalertinib: Clinical Trials

7 trials of zipalertinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 not yet recruiting, 2 recruiting, 1 available. 4 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Not yet recruiting 2, Active not recruiting 1, Recruiting 1
Phase 32Active not recruiting 1, Recruiting 1
Phase 11Active not recruiting 1

Follow zipalertinib: new trials by email Literature Review of zipalertinib trials Research Report on zipalertinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Squamous Non-Small Cell Carcinoma
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center162027-06-012026-02-05
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
Zipalertinib - EGFR, Lung Cancer (NSCLC)
Phase 2Not yet recruitingStanford University422026-11-012026-09-03
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
TAS6417, Zipalertinib Matching-placebo - Lung Cancer, Adjuvant
Phase 3RecruitingTaiho Oncology, Inc.3602025-12-222026-10-13
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
TAS6417 - Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Phase 3Active not recruitingTaiho Oncology, Inc.2852023-12-182026-11-03
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
TAS6417, CYP Cocktail, Transporter Cocktail - Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Phase 2RecruitingTaiho Oncology, Inc.2202023-07-312026-10-06
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
CLN-081 - Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Phase 1 / Phase 2Active not recruitingCullinan Therapeutics Inc.2842019-10-312026-06-17
An EAP Treatment Protocol of Zipalertinib
Zipalertinib - Non-Small Cell Lung Cancer
AvailableTaiho Oncology, Inc.2026-06-11

Conditions studied

Carcinoma, Non-Small-Cell Lung (5)  ·  Lung Diseases (2)  ·  Lung Neoplasms (2)  ·  Carcinoma (1)

Sponsors

Taiho Oncology, Inc. (4)  ·  Cullinan Therapeutics Inc. (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Stanford University (1)

Countries

United States (5)  ·  Italy (4)  ·  Japan (4)  ·  South Korea (4)  ·  Spain (4)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Hong Kong (3)  ·  Netherlands (3)  ·  Singapore (3)  ·  Turkey (Türkiye) (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Belgium (2)

Top investigators

Arjan Gower, MD (1)  ·  Joel Neal, MD (1)  ·  Zosia Piotrowska, MD (1)

Results publications

PMID 33122578, PMID 37384848, PMID 39957151, PMID 40450572

NIH funding

2023 (2), 2025 (1)